Circadian regulation of NAMPT in the heart
Circadian regulation of NAMPT in the heart
批准号:
10688124
负责人:
Lilei Zhang
金额:
$20.0万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-08-22 至 2024-07-31
关键词:
BindingBiological ProcessBiologyBrainCardiacCardiac MyocytesCardiovascular DiseasesCardiovascular systemCellular biologyChromatin LoopChronotherapyClinical TrialsComplexDataDependovirusDiseaseEctopic ExpressionElementsEnhancersEnzymesFibroblastsFoundationsFunding OpportunitiesGene ExpressionGene Expression RegulationGenesGenetic Enhancer ElementGenetic TranscriptionGenus HippocampusGoalsGuide RNAHeartHomeostasisHumanIn VitroIntronsIschemiaKnock-inKnockout MiceLifeLiverLongevityMammalian CellMeasuresMetabolismMethodsModelingMolecularMusMuscleMyocardialMyocardial IschemiaMyocardiumNiacinamideNicotinamide adenine dinucleotidePathway interactionsPeriodicityPhasePhysiologicalPhysiologyPlayPre-Clinical ModelPredispositionProteinsRegulationReperfusion InjuryReperfusion TherapyResistanceRoleSiteSlaveSupplementationSystemTechnologyTestingTetracyclinesTherapeutic UsesTimeTissuesTransfectionUp-RegulationWorkZinc Fingersbiological systemscardiovascular healthchromosome conformation capturecircadiancircadian regulationdesignheart metabolismin vivoinduced pluripotent stem cellinsightmouse modelnicotinamide phosphoribosyltransferasenovelprime editingprime editorpromoterresilienceresponsesmall moleculestem cell differentiationtherapeutic evaluationtooltranscription factor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
Nicotinamide or NAD+ is one of the most essential small molecules in mammalian cells. Its roles in
cardiovascular health and longevity are increasingly being appreciated. As a result, its therapeutic use is being
tested in numerous clinical trials. Nicotinamide phosphoribosyltransferase (NAMPT) is the rate-limiting enzyme
of the NAD+ salvage pathway and determines NAD+ level in the heart. Both NAD+ levels and NAMPT have a
strong circadian oscillation in the heart. The molecular mechanism for NAD+ circadian regulation is only partially
understood. The physiological significance of oscillating NAD+ has not been directly tested in preclinical models.
Thus, this information has not been incorporated in any of the existing clinical trials.
Our goal in this application is to determine the molecular mechanism of NAMPT circadian regulation and
establish the physiological significance of oscillatory NAD+ in the heart. Based on our preliminary data, we
hypothesize that co-occupancy of BAML1 and KLF15 in a promoter-enhancer loop is required for optimal
upregulation of Nampt in a time-of-a-day dependent fashion. This coordinated circadian regulation is key for
oscillatory myocardial NAD+, cardiac metabolism and I/R resistance. To test this central hypothesis, we designed
two complementary aims to first determine the molecular mechanism of NAMPT circadian regulation in both
induced pluripotent stem cell differentiation cardiomyocytes (iPSC-CM) and mouse hearts. Novel prime editing
technology will be used to generate cis-element deleting iPSC-CM and mouse models in addition to traditional
cardiac KO mice. In the second aim, we will use our novel tetracycline inducible adeno-associated virus (AAV
system) to test the physiological effect of in-phase, anti-phase and constant expression of NAMPT in cardiac
metabolism and resistance to ischemia/reperfusion injury.
Successful completion of the proposed work will allow us to (1) establish the precise molecular
mechanism of circadian oscillatory regulation of cardiac NAD+, and (2) understand the functional significance of
oscillatory Nampt expression in the heart. This will further shed light on the molecular mechanism of tissue
specific circadian gene regulation, which is very poorly appreciated at this time. We established the first cardiac
“slave” clock (KLF15) and here we first proposed the core clock-slave clock promoted chromatin looping model,
in contrast to the linear core clock>slave clock>targets model. In addition to the conceptual novelty, we generated
novel prime editing tools that allow precise editing in iPSC-CM as well as in a special-temporal regulated fashion
in vivo. We also designed novel method to first time test the physiological consequence of oscillatory expression
versus constant expression.
Our proposed work directly responds to the current Funding Opportunity PA19-0-49, “studying normal
biology including homeostatic regulation of biological systems and the phenomenon of resilience”, “defining the
basic pathways that underlie effects of circadian function, synchronization and harmonization”.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Deciphering the role of a circadian lncRNA in cardiac remodeling
-
批准号:10599336
-
项目类别:
-
资助金额:$71.94万
-
财政年份:2022
-
负责人:Lilei Zhang
-
依托单位:
Deciphering the role of a circadian lncRNA in cardiac remodeling
-
批准号:10442269
-
项目类别:
-
资助金额:$71.68万
-
财政年份:2022
-
负责人:Lilei Zhang
-
依托单位:
Circadian regulation of NAMPT in the heart
-
批准号:10509597
-
项目类别:
-
资助金额:$20.0万
-
财政年份:2022
-
负责人:Lilei Zhang
-
依托单位:
Transcriptional regulation of cardiac pathological remodeling by REV-ERBα
-
批准号:9927666
-
项目类别:
-
资助金额:$48.98万
-
财政年份:2019
-
负责人:Lilei Zhang
-
依托单位:
Transcriptional regulation of cardiac pathological remodeling by REV-ERBα
-
批准号:10171416
-
项目类别:
-
资助金额:$47.47万
-
财政年份:2019
-
负责人:Lilei Zhang
-
依托单位:
Transcriptional regulation of cardiac pathological remodeling by REV-ERBα
-
批准号:10447818
-
项目类别:
-
资助金额:$45.88万
-
财政年份:2019
-
负责人:Lilei Zhang
-
依托单位:
Transcriptional regulation of cardiac pathological remodeling by REV-ERBα
-
批准号:10610880
-
项目类别:
-
资助金额:$44.78万
-
财政年份:2019
-
负责人:Lilei Zhang
-
依托单位:
Role of KLF15 in Circadian Regulation of Cardiac Ischemia
-
批准号:9032864
-
项目类别:
-
资助金额:$16.42万
-
财政年份:2016
-
负责人:Lilei Zhang
-
依托单位:
Role of KLF15 in Circadian Regulation of Cardiac Ischemia
-
批准号:9204850
-
项目类别:
-
资助金额:$16.42万
-
财政年份:2016
-
负责人:Lilei Zhang
-
依托单位:
海外基金